Biomerica
Makes rapid diagnostic tests and GI-focused laboratory assays for clinical and consumer use.
Something off on this page? Send us feedback.
Profile
Sells rapid and ELISA diagnostic tests, laboratory assays and consumer kits, with contract development and manufacturing alongside product sales. GI-focused inFoods and hp+detect add a laboratory-service pathway to a business manufactured in Irvine and Mexicali and distributed internationally.
Develops, manufactures and sells in-vitro diagnostic products spanning rapid and ELISA tests, laboratory assays, and consumer and point-of-care kits. The portfolio includes the inFoods IBS food-elimination assay, hp+detect H. pylori stool-antigen test, EZ Detect occult-blood test, and Aware breast self-exam pad.
Centers administration, regulatory work, product development, and primary manufacturing in Irvine, while Mexicali handles lower-cost assembly and manufacturing and BioEurope supports international distribution. Products reach clinical laboratories, health-care practices, retailers, e-commerce customers, and distributors; contract R&D and private-label manufacturing add a service revenue stream.
Relies increasingly on laboratory adoption and reimbursement for inFoods. Sales are geographically diversified but weighted outside North America, and ongoing operations depend on regulatory compliance, foreign distribution, supply continuity, and capital availability.
Company facts
Key statistics
Year to date −15.4% · Average volume (30d) 118.6K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Apr 13, 2026Q3 FY26 | −$1.20 | −$0.44 | +63.3% | $3.6M | $987.0K | −72.8% | +0.96% |
| Jan 14, 2026Q2 FY26 | — | −$0.45 | — | — | $1.2M | — | −0.74% |
| Oct 14, 2025Q1 FY26 | — | $0.00 | — | — | $1.4M | — | −0.69% |
| Sep 1, 2025Q4 FY25 | $0.32 | −$0.16 | −150.0% | $3.1M | $749.0K | −75.8% | −4.15% |
Financial highlights
| 12 quarters | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.6M | $1.1M | $749.0K | $1.4M | $1.2M | $987.0K | |
| Gross profit | $437.0K | $19.0K | −$244.0K | $424.0K | $51.0K | −$44.0K | |
| Operating income | −$993.0K | −$1.2M | −$1.6M | −$1.1M | −$1.4M | −$1.3M | |
| Net income | −$950.0K | −$1.2M | −$1.5M | $2.0K | −$1.3M | −$1.3M | |
| Diluted EPS | −$0.06 | −$0.07 | −$0.16 | $0.00 | −$0.45 | −$0.44 | |
| Gross margin | 26.7% | 1.7% | -32.6% | 30.7% | 4.2% | -4.5% | |
| Operating margin | -60.7% | -108.1% | -208.8% | -81.0% | -113.5% | -131.5% |
Fiscal years (4-quarter sums)FY21 $7.2M · FY22 $18.9M · FY23 $5.3M · FY24 $5.4M · FY25 $5.3M
Revenue by geography · Q1 FY26
Balance sheet, Feb 28, 2026Cash & short-term investments $1.3M · Total debt $193.0K · Total assets $4.9M · Shareholders' equity $3.3M
Dividends
No dividends on record.
Ownership
Shares outstanding 3.09M · Float —
Float — provider float is below the insider stake.
The provider's float is smaller than the insider stake it should exclude, so it is not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| B. Riley Principal Capital, LLC | 460.1K | 10.03% | 13D | Aug 28, 2026 |
| Zackary S. Irani · director, officer: Chief Executive Officer | 242.6K | 7.85% | Form 4 | Aug 27, 2026 |
| Allen Barbieri · director, officer: Executive Vice Chairman | 73.5K | 2.38% | Form 4 | Aug 27, 2026 |
| Gary Lu · officer: Chief Financial Officer | 59.4K | 1.92% | Form 4 | Dec 31, 2025 |
| Geode Capital Management, LLC | 56.0K | 1.81% | 13F | May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 26, 2026 | Allen Barbieri | director, officer: Executive Vice Chairman | +20,000 | $1.60 |
| Aug 26, 2026 | Eric Chin | director | +6,250 | $1.60 |
| Aug 26, 2026 | David Moatazedi | director | +10,000 | $1.60 |
| Aug 20, 2026 | M. Huff Gary | director | +31,250 | $1.60 |
| Aug 26, 2026 | Zackary S. Irani | director, officer: Chief Executive Officer | +31,250 | $1.60 |
Peers
- Abbott
Broad clinical-lab and rapid diagnostics pressure.
- QuidelOrtho
Direct H. pylori stool-antigen testing overlap.
- Danaher
Large clinical-lab immunoassay and GI-testing incumbent.
- Ironwood Pharmaceuticals
IBS-C treatment competes for gastroenterology adoption.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Biomerica | $2.14 | 0.00% | $6.6M | — | — | 1.5 | −11.8% |
| Abbott | $112.20 | −0.22% | $194.62B | 36.2 | 19.4 | 4.2 | +13.0% |
| QuidelOrtho | $14.70 | −0.27% | $1.01B | — | 17.5 | 0.4 | +2.6% |
| Danaher | $215.50 | −0.25% | $151.89B | 38.4 | 24.3 | 6.0 | +5.5% |
| Ironwood Pharmaceuticals | $4.12 | −0.06% | $679.9M | 5.4 | 3.5 | 1.7 | +32.6% |
| Median | 36.2 | 18.4 | 3.0 | +9.3% |